CCR7 and colorectal carcinoma: To address the effect of ICB on CCR7+ DCs, we administered anti-PD-L1 antibodies in this model (Supplementary Fig. 2a), selecting this target because CCR7+ DCs in CRC showed the highest expression of PD-L1 among immune cells (Supplementary Fig. 1c).